Dosage Lookup

GLP-1 Agonists

2.6

Moderate

consensus

Doses are escalated slowly over months to limit GI side effects — semaglutide from 0.25mg up to 2.4mg/week, tirzepatide from 2.5mg up to 15mg/week. See the week-by-week titration schedule below. Dosing is individualized by a prescribing physician (Attia).

Based on expert consensus data from publicly available videos, not medical advice. Always consult your healthcare provider before starting, stopping, or changing any supplement.

Consensus Protocol

Dosage

Doses are escalated slowly over months to limit GI side effects — semaglutide from 0
25mg up to 2
4mg/week, tirzepatide from 2
5mg up to 15mg/week
See the week-by-week titration schedule below
Dosing is individualized by a prescribing physician (Attia)

Form

Injectable (subcutaneous, once weekly) remains the mainstay and still leads on peak efficacy
Oral GLP-1s are now FDA-approved too — oral semaglutide (the Wegovy pill, Dec 2025) and the non-peptide orforglipron (Apr 2026)
Some clinicians use compounded peptide formulations at lower doses (Attia, Koniver)

Timing

Once-weekly injection
No specific time-of-day requirement
Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia)

Notes

This is a prescription medication — not a supplement
Requires physician oversight, regular monitoring via DEXA scans for body composition, and blood work
Compounded versions from reputable pharmacies may offer lower-dose options
High cost remains a significant barrier to access (Attia)
Hyman strongly advocates addressing diet and lifestyle first before considering pharmaceutical intervention

Expert Positions

Andrew Huberman

Favorable — Covers Science Extensively

Peter Attia

Strongly Favorable with Caveats

Rhonda Patrick

Limited Direct Coverage

Bryan Johnson

Limited Direct Coverage

Mark Hyman

Strongly Opposes Widespread Use

What Each Expert Says

Andrew Huberman

Favorable — Covers Science Extensively

Huberman covers GLP-1 agonists across multiple contexts: hunger neuroscience, peptide therapy, and fat loss protocols. He features Dr. Zachary Knight (UCSF) explaining the mechanism of GLP-1 drugs, their origin from Gila monster venom, and the evolution from short-acting to long-acting forms. He discusses how GLP-1 acts on brain stem and hypothalamic circuits to suppress appetite. In peptide therapy episodes, Dr. Craig Koniver discusses micro-dosing semaglutide and tirzepatide to mitigate side effects. Huberman also frequently mentions yerba mate as a natural GLP-1 stimulator for fat loss.

Unlock Expert Deep Dives

See exactly what each expert recommends — specific dosages, forms, timing protocols, and video citations with timestamps.

Cancel anytime

More on GLP-1 Agonists

Consensus Score Which Form? When to Take Check Your Stack

Common Questions

How much GLP-1 Agonists should you take?

What form of GLP-1 Agonists is best?

Injectable (subcutaneous, once weekly) remains the mainstay and still leads on peak efficacy. Oral GLP-1s are now FDA-approved too — oral semaglutide (the Wegovy pill, Dec 2025) and the non-peptide orforglipron (Apr 2026). Some clinicians use compounded peptide formulations at lower doses (Attia, Koniver).

When should you take GLP-1 Agonists?

Once-weekly injection. No specific time-of-day requirement. Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia).

All dosage lookups